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Abstract 
New technologies and therapies designed to facilitate development of personalized treatments are rapidly emerging 
in the field of biomedicine. Strikingly, the goal of personalized medicine refined the concept of therapy by develop‑
ing cell‑based therapies, the so‑called “living drugs”. Breakthrough advancements were achieved in this regard in the 
fields of gene therapy, cell therapy, tissue‑engineered products and advanced therapeutic techniques. The Advanced 
Therapies in Healthcare symposium, organized by the Clinical Research Center Department of Sidra Medicine, in 
Doha, Qatar (October 2017), brought together world‑renowned experts from the fields of oncology, hematology, 
immunology, inflammation, autoimmune disorders, and stem cells to offer a comprehensive picture of the status of 
worldwide advanced therapies in both pre‑clinical and clinical development, providing insights to the research phase, 
clinical data and regulatory aspects of these therapies. Highlights of the meeting are provided in this meeting report.
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Introduction
The Advanced Therapies in Healthcare (ATH) sympo-
sium (http://event s.sidra .org/event /advan ced-thera pies-
in-healt hcare /), held in Doha, Qatar (October 2017), 
offered an outstanding combination of talks, capturing a 
broad range of topics in the area of advanced therapies 
worldwide (Table 1).
This meeting report summarizes the key advancements 
presented in the symposium, in the areas of gene therapy, 
cancer immunotherapy, cell therapy/adoptive cell ther-
apy, diabetes and general therapeutic techniques.
Gene therapy
During last decade, the field of gene therapy has enor-
mously progressed, regaining its “fame” after the whole 
world held its breath for the first viral-insertion oncogen-
esis events. Cases of overt leukemias in X-linked Severe 
Combined Immune Deficiency (SCID-X) immunodefi-
cient patients treated with retroviral vectors-corrected 
stem cells placed the whole field in the eye of the storm in 
the early 2000s [1].
In 2016, after proving its safety with years of studies 
on clonal insertion, of vector improvements and robust 
follow-ups, gene therapy matured, from the infancy of a 
few case reports cured by gifted scientists, into the pro-
duction of its first commercial drug.
Gene therapy also changed the whole concept of a 
“drug”, introducing the frame of a “process”, entailing a 
few days of high-level cell manufacturing, and resulting 
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in a therapeutic product that can be defined as a “living 
drug” [2].
The first gene therapy drug to hit the market was Strim-
velis, a gamma-retroviral based hematopoietic stem cell 
gene therapy process for ADA-SCID patients [3, 4].
The concomitant breakthrough of CAR-T cells 
launched two more commercial drugs in the following 
years. CAR-T cells targeting the CD19 molecule are now 
available in the market for relapsed/refractory B-ALL and 
diffuse large B cell lymphoma treatment in two different 
Table 1 Summary of speakers and topics
Speaker Title Clinical Application
Adrian Thrasher Evolving gene therapy for primary immunodeficiency Primary immunodeficiencies
Matthew Porteus Genome editing of stem cells to cure genetic diseases of the 
blood and immune system
Sickle cell disease
SCID‑X1
Waseem Qasim Gene engineered immune therapy Cancer (B‑ALL)
Ramsay Fulham Stem cell transplantation (reduced intensity conditioning) and 
obstacles and new approaches to Gene Therapy for hyper 
IgM syndrome
Hyper IgM syndrome
Antonia Follenzi Cell and gene therapy for hemophilia A Hemophilia A
Katarina Le Blanc MSC in clinical trials for type 1 diabetes Diabetes
Maria Ester Bernardo Autologous bone marrow‑derived mesenchymal stromal cells 
in the treatment of fistulising Crohn’s disease
Crohn disease
Patrizia Comoli Antigen‑specific T cell therapy in hematology/oncology Viral infections in immunosuppressed patients (EBV, CMV, HHV6, 
BK, JCV)
Essam Abdelalim Pluripotent stem cell‑derived pancreatic beta cells: therapeu‑
tic potential and challenges in diabetes treatment
Diabetes
Lorenzo Piemonti Toward beta cell replacement for diabetes Diabetes
Peter Parham HLA and KIR in human health and survival NK mediated immune responses
Graham Davies Thymus transplantation Primary thymic disorders
Mamoun Elawad Allogeneic HSCT for inflammatory gut diseases Inflammatory gut diseases bowel disease
Amel Hassan Hematopoietic stem cell transplant for PID Primary immunodeficiencies
Raya Saab Genomics of childhood cancer Pediatric cancers
Amar Gajjar Molecularly directed therapy for pediatric brain tumors Pediatric cancers
Massimo Gadina Inhibition of cytokine signaling in autoimmune and inflamma‑
tory diseases: the coming of age of JAK inhibitors
Autoimmune diseases
Holm Uhlig New non‑transplant approach in treating CGD and primary 
neutropenia
Inflammatory bowel disease, CGD, primary neutropenia
Soldano Ferrone HLA antigens and immunotherapy of malignant diseases Cancer (melanoma, head and neck squamous cell carcinoma, 
breast cancer)
Michele Maio Immune checkpoint inhibitors Cancer (melanoma, lung carcinoma, colorectal cancer, mesothe‑
lioma)
Francesco Marincola Addressing cancer responsiveness immunotherapy Cancer (immune responsiveness)
Giampietro Dotti Car‑T cells: from bench to bedside Cancer (CD19+ cancers, glioblastoma, ductal adenocarcinoma, 
ovarian cancer, neuroblastoma)
Kevin Curran CAR T‑cell for cancer immunotherapy Cancer (B‑ALL)
Stephen Hunger Treatment of relapsed pediatric acute lymphoblastic leukemia. 
The promise of CAR T‑cell therapy
Cancer (B‑ALL)
David Stroncek CAR‑T cells: promise and problems CAR‑T cell manufacturing
Winfried Wels CAR‑engineered NK cells for adoptive cancer immunotherapy Cancer (Glioblastoma)
Ziyad Hijazi Current state of percutaneous pulmonary valve replacement Cardiac surgery
Goran Petrovski Closing the loop in diabetes: the impact of sensor augmented 
pump
Diabetes
Abdalla Zarroug Intrauterine surgery Fetal surgery
Fawzi Teskrat Inspection of ATMP’s activities Quality and compliance
Eoin McGrath JACIE accreditation: an overview Quality and compliance
Eoin McGrath New therapies: adapting standards and regulations to 
immune effector cells
Quality and compliance
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flavors: Kymriah (Tisagenlecleucel, gamma-retroviral 
based) and Yescarta (axicabtagene ciloleucel, also called 
axi-cel, lentiviral based).
A brief historical overview: gene therapy of primary 
immune deficiencies
Fifty years ago, SCIDs were fatal diseases, and only after 
the introduction of allogeneic hematopoietic stem cell 
transplantation (HSCT) and exogenous enzyme replace-
ment the first clinical responses were gained. Nowadays 
a stable cure has been achieved through gene therapy 
approaches.
Long-term disease-free survival of different Adenosine 
Deaminase (ADA)-SCID gene therapy clinical trials in 
Europe and US ranges from 50 to 83% [5].
The oncogenic adverse events occurring in SCID-X [1] 
paved the way to the development of refined vector tech-
nologies, including the use of self-inactivating gamma-
retroviral and lentiviral vectors in which the powerful 
viral enhancer sequences are deleted. Clinical trials with 
these vectors have now been reported, including SCID-
X (RV; NCT01410019, NCT01175239, NCT01129544), 
Wiskott-Aldrich syndrome (WAS; LV; NCT01347242), 
ADA-SCID (LV; NCT01380990 and NCT02234934) and 
Chronic Granulomatous Disease (LV; NCT02234934, 
NCT01347346), with encouraging preliminary results of 
enhanced safety and long-term efficacy [6]. Some of these 
products are being lined up for regulatory licensing.
Furthermore, new technologies, including homolo-
gous recombination or gene repair to accurately correct 
genetic mutations or insert therapeutic sequences, are on 
their way towards clinical translation.
Gene therapy of hemophilia A
Hemophilia A is a monogenic X-linked disease caused by 
the lack of Factor VIII, and it is very life-compromising 
in its severe form. A very modest protein product of the 
missing gene would be able to functionally correct the 
disorder, making the disease an optimal target for gene 
therapy.
Adenoviral vector (AAV)—mediated gene therapy tar-
geting the liver was able for the first time in clinical trials 
to achieve a long-term clinical benefit both for Hemo-
philia A and B—with some “caveats”: candidate patients 
should not possess natural anti-AAV antibodies and—the 
liver being very immunogenic—signs of transaminitis. 
These clinical conditions will lead to an immune rejection 
of the transgene expressing cells and, thus, will immedi-
ately require high dose steroids to preserve the integrity 
of the therapy.
Lentiviral vectors may be able to deliver FVIII 
transgene to target cells, with less immunogenicity. Liver 
endothelial sinusoidal cells and Kupffer cells are the 
main FVIII producers in the liver. By using cell-specific 
promoters, optimized with miRNA, a tolerizing pattern 
towards the transgene was shown in mice, mediated by 
T-regs intervention. Moreover, by using an endothe-
lial specific promoter (Vascular Endothelial Cadherin 
5), long term transgene expression in mice is observed 
with no immune responses [7]. Novel gene transfer tech-
nologies include a striking gene delivery “immune-pro-
tected” system where gene modified cells would release 
the transgene through a small implantable device (Cell 
Pouch™ http://www.serno va.com/techn ology /).
Gene editing of stem cells (sickle cell disease, SCID‑X1)
Gene editing represents a promising approach to 
improve the clinical efficacy of gene therapy. The first 
CRISPR/Cas9 gene-editing platform for repairing the 
β-globin gene in hematopoietic stem cells was reported 
in 2016 [8]. A combination of Cas9 ribonucleoproteins 
and AAV donor DNA delivery was able to precisely 
repair the sickle cell disease causing E6V mutation in the 
β-globin gene in patients’ hematopoietic stem cells. The 
gene expression recovery was highly efficient, with repro-
ducibility and acceptable low off-target reactivity among 
patients.
Further optimization of the delivery method by using a 
High Fidelity Caspase 9 technique (from Integrated DNA 
Technologies, IDT) significantly reduced the off-target 
editing, while maintaining the on-target performance, 
with a final rate of 40–50% gene-corrected cells [9].
Similar striking results were also obtained in SCID-X1 
immunodeficiency through repairing the IL-2 gamma-
chain receptor in stem cells. Two Phase I/II trials are to 
commence in 2019 in Stanford for both hemoglobinopa-
thies and primary immunodeficiencies.
Gene therapy of cancer—the CARs (T and NK)
Clinical efficacy of CARs
Survival rates for children and adolescents with acute 
lymphoblastic leukemia (ALL) have improved steadily 
over the past 5 decades, with 5-year overall survival (OS) 
now exceeding 90% [10–12]. However, high risk sub-
groups of newly diagnosed ALL patients can be identified 
that have an OS < 60% [13] due to high rates of disease 
relapse, particularly bone marrow relapse [14]. Further-
more, only a small portion of children and adolescents 
that experience a 2nd relapse, or relapse after a prior allo-
geneic HSCT, are cured by salvage therapies. Intensifica-
tion of standard cytotoxic chemotherapy agents and/or 
HSCT have not significantly improved OS for these very 
high risk subgroups of newly diagnosed and relapsed 
ALL, identifying a major unmet medical need.
The Children’s Hospital of Philadelphia (CHOP)/
Univeristy of Pennsylvania (Penn) group is among the 
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first pioneers of adoptive cell therapy treatment of ALL 
patients with CTL019 (tisagenlecleucel) CAR-T cells. 
Among an initial cohort of 25 children recruited at 
CHOP and 5 adults recruited at the University of Penn-
sylvania Hospital (NCT01626495 and NCT01029366) 
with relapsed/refractory B-ALL, 90% attained com-
plete responses (CR) [15]. All patients developed the 
Cytokine-Release Syndrome (CRS), which was of a high 
grade (3–4) in 27% of cases. Patients with severe CRS 
were rescued successfully with the interleukin-6 receptor 
monoclonal antibody (mAb) tocilizumab. With a follow 
up period of 2–24 months, half of the cohort remained in 
complete remission, with most receiving no further leu-
kemia therapy.
The pediatric cohort of the clinical trial was increased 
to 60 subjects and was followed over time. The CR rate 
was 93%. After a median follow up of 15 months (1–48 
mos), 24 patients out of 60 showed continuous remission 
over 1 year in duration; moreover, 19 of these patients did 
not require other therapies.
These results are particularly remarkable and unprec-
edented as 2/3 of treated patients had undergone a prior 
allogeneic HSCT, meaning that CAR-T cell strategy can 
restore sustained anti-cancer immune responses even 
after failure of graft versus leukemia (GVL) responses.
A multicenter Phase II study (ELIANA; NCT02435849) 
with CTL019 CAR-T cells has been performed enroll-
ing patients in US Canada, Europe, Australia and Japan 
[16]. Among 75 patients with sufficient follow-up, over 
80% of patients achieved remission, which was complete 
in three-quarters of patients and was with incomplete 
blood count recovery in the remaining quarter. Patients 
with complete clinical responses had no detectable 
minimal residual disease. Disease-free survival was 73% 
at 6 months and 50% at 12 months, and OS was 90% at 
6 months, and 76% at 12 months. This clinical study led 
to the first approval by the Food and Drug Administra-
tion (FDA) of tisagenlecleucel.
Another Phase I Multicenter Trial administered CD19 
CAR-T cells to young adult patients with relapsed/refrac-
tory B-ALL (NCT01860937). CAR-T cells were manu-
factured at the Memorial Sloan Kettering Institute, NY, 
USA, and patients were recruited and treated at the Dana 
Farber Cancer Institute and Boston Children’s Hospital, 
Boston, USA. In 24 evaluable patients, CR rate was 75%, 
significantly better after high dose cyclophosphamide 
(Cy) vs low dose chemotherapy, while the addition of 
Fludarabine to the therapeutic regimen did not provide 
significant benefits. Pre-treatment molecular remission 
was decisive for OS, granting a plateau of survival over 
500 days for about 75% of this patient group.
Natural killer (NK) cells represent a valuable innate 
immune cell population for adoptive cell therapy, but 
clinical experience with CAR-engineered NK cells is still 
limited. In cancer patients, NK cells, like other immune 
cells, are often functionally compromised due to the 
immunosuppressive features of the tumor microenviron-
ment (TME). Hence, for adoptive cell therapy, donor-
derived allogeneic NK cells are preferable since they do 
not recognize tumor cells as “self”, thereby bypassing 
inhibitory signals. It is possible to exploit the therapeu-
tic efficacy of NK cells through expression of CARs, using 
the NK-92 cell line. This clinically applicable cytotoxic 
cell line provides an unlimited source of effector cells and 
holds potential for development as a standardized “off-
the-shelf” therapy [17].
GMP-compliant protocols for vector production, len-
tiviral transduction and expansion of a CAR-engineered 
cell clone (NK-92/5.28.z) were established which carries 
a HER2 (ErbB2)-specific CAR that harbors a composite 
CD28-CD3ζ signaling domain [18]. Functional analysis of 
NK-92/5.28.z cells revealed high and stable CAR expres-
sion, and selective cytotoxicity against HER2-positive 
tumor cells of different origins. Importantly, upon acti-
vation, NK-92/5.28.z cells could secrete high levels of 
proinflammatory factors without upregulating immune 
checkpoint molecules. CAR-mediated cytotoxicity was 
not affected by immunosuppressive factors such as a 
hypoxic environment and TGF-β. With the aim of devel-
oping NK-92/5.28.z cells for the treatment of HER2-
positive glioblastoma multiforme (GBM), the reactivity 
of these cells against GBM cell lines and primary GBM 
cultures was evaluated, showing selective HER2-depend-
ent cell killing in  vitro. Potent in  vivo anti-tumor activ-
ity of NK-92/5.28.z was observed in orthotopic GBM 
xenograft models in NOD scid common gamma chain 
knockout (NSG) mice, leading to a marked extension 
of OS upon repeated stereotactic injection of CAR-
NK cells into the tumor [17, 19]. In immunocompetent 
transplanted syngeneic GBM animals, local therapy with 
NK-92/5.28.z cells resulted in induction of endogenous 
antitumor immunity and long-term protection against 
tumor rechallenge at distant sites. These results suggest 
that adoptive cell transfer of HER2-specific NK-92/5.28.z 
cells represents a promising immunotherapy approach 
for GBM. A Phase I clinical trial investigating intracranial 
injection of NK-92/5.28.z cells as a treatment for recur-
rent HER2-positive GBM is ongoing (NCT03383978).
Side effects of CARs
CARs have also of course their limits and pitfalls. The 
first side effect is represented by CRS, caused by a large, 
rapid release of cytokines into the blood from immune 
cells affected by the immunotherapy: all patients in the 
initial CHOP/Penn cohort and 80% of patients of Memo-
rial Sloan Kettering Institute developed some degree 
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of CRS, with a wide range of severity. At least 50% of 
patients required admission to Intensive Care Units, and 
15–30% of them battled against life threatening compli-
cations. The toxicities of CAR T-cell therapy are not only 
acute, but also include B-cell lymphopenia, since normal 
B-cells express CD19. The lymphopenia is associated 
with low levels of immunoglobulin production such that 
patients usually required regular intravenous immuno-
globulin infusions to restore a protective humoral immu-
nity, while CAR-T cells are detectable in their body.
To increase the safety of CAR-T cells, a “safety switch” 
can be used [20, 21], allowing the termination of CAR-T 
cell survival in case of toxicity.
The potent iC9 system is based on a modified human 
caspase-9 fused to the human FK506 binding protein 
(FKBP), sensitive to AP1903/Rimiducid drug. After 1 
dose drug delivery, > 85–90% of iC9-transduced T cells 
are rapidly eliminated, with the advantage of leaving 
behind a residual efficient population that can be re-
expanded in the event of a tumor relapse [22].
After the construct was validated in a mouse model, the 
LC Cancer Center University of North Carolina—Chapel 
Hill initiated a clinical trial to evaluate the safety and 
efficacy of this therapy in N = 40 patients with relapsed/
refractory B-ALL (NCT03016377).
Target “antigens” for CARs
Almost 20 clinical trials ongoing worldwide are trying 
to expand CARs cell therapy in solid cancer diseases, 
including breast cancer, nasopharyngeal carcinoma, lung 
cancer, cervical cancer, colorectal cancer, pancreatic can-
cer, head and neck cancer, and brain cancers (https ://
clini caltr ials.gov/ct2/resul ts?cond=Cance r&term=CAR-
T&cntry =&state =&city=&dist=&Searc h=Searc h).
Chondroitin sulfate proteoglycan 4 (CSPG4) is a pro-
tein overexpressed by tumors with different histological 
origins, such as GBM, astrocytoma, head and neck can-
cers, renal clear cell carcinoma, triple negative breast 
cancer and melanoma. Particularly in GBM, this antigen 
has been detected in cancer stem cells and tumor-associ-
ated vessels. The intracranial injection of CSPG4.CAR-T 
cells successfully controlled tumor growth in mice ortho-
topically xenografted with GBM cells. A “first in man” 
Phase I clinical study is being planned in LC Cancer 
Center University of North Carolina—Chapel Hill for 
GBM patients, treated with CSGP4.CAR T cells, with the 
iC9 safety switch.
Another appealing target molecule for CAR-T cells is 
represented by B7-H3 which is a member of the B7 family 
aberrantly expressed by cancer and stroma fibroblasts in 
ovarian and pancreatic cancers, GBM and several other 
type of tumors. Promising results have been obtained in 
mouse models using anti-B7-H3 CAR-T cells. A Phase 
I clinical study for patients with ovarian cancer is also 
planned for this target molecule.
Moreover, neuroblastoma patients are benefitting from 
T-cells engineered with a 3rd generation (CD28-OX40) 
anti-GD-2 CAR-T construct, associated with an iC9 sui-
cide safety switch, in the GRAIN study (NCT01822652), 
sponsored by Baylor College of Medicine. Interim results 
show that three out of 11 patients (27%) achieved a CR, 
however only 1 patient showed durable responses. The 
study is also aimed at comparing the clinical efficacy of 
the combination regimen of CAR-T cells with one anti-
PD-1 agent, Pembrolizumab, which usually is not clini-
cally effective in patients with this type of tumor.
Target “patients”
In front of an urgent clinical need, as often is the case 
of overt relapses unresponsive to salvage therapies, and 
when patients are not adequate for leukapheresis self-
donation, the only available starting material to generate 
CAR-T cells is represented by third party blood cells.
To overcome the immunological barrier linked to the 
CAR-T cell design, some scientists are developing a com-
bined approach with a 2-step engineering method: the 
insertion of CAR-T construct, plus gene editing to elimi-
nate the native T-Cell Receptor (TCR) of T-lymphocytes. 
This strategy will reduce the possibility of causing Graft 
versus Host Disease (GvHD) and will represent the gen-
eration of “off-the-shelf” CAR-T cells.
CAR-T cells engineered to lack CD52 and TCR anti-
gens through TALEN-mediated gene editing- “Uni-
versal” CD19-targeting cells (U-CART19) are now 
available in a Phase I study at the UCL/Great Ormond 
Street Hospital, in collaboration with Belgium and France 
(NCT02808442). The CAR product was launched after 
the successful application of a pilot study at UCL. In 
two cases of ALL pediatric patients who relapsed after 
allo-HSCT, the U-CART19 therapy was able to regain 
ALL molecular remission after other salvage therapies—
including Blinatumomab—failed. Patients successfully 
underwent a second allo-HSCT thereafter.
Gene edited U-CART showed encouraging results on 
remission rates while their long-term safety and efficacy 
are still under evaluation.
Relapse after CAR‑T cell therapy
Mechanisms of immune evasion are common in tumor 
cells to impair anti-tumor immune responses [23]. One 
of these mechanisms is represented by immune selec-
tion of tumor cells negative for the expression of defined 
antigens [24]. CAR-T cells, through targeting one single 
antigen, are not very versatile and became ineffective in 
tumor recognition upon failure of tumor cells to express 
a specific antigen. The strategy to develop CAR-T cells 
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targeting multiple tumor antigens seems the best one to 
overcome this issue [25].
Another factor limiting CAR-T cells’ anti-tumor activ-
ity is their persistency. CAR-Ts with long lasting “central 
memory” phenotype [26] showed the highest persistence 
in  vivo, therefore it is crucial to strategize a protection 
from their late stage of cellular differentiation [27]. Long 
lasting persistency may be also hampered by immune-
mediated targeting of murine antigens in the construct. 
The CTL119-CAR-T cell construct, which uses a human-
ized version of the B-cell moiety, has been tested at 
CHOP/Penn with a 100% CR rate in 22 Relapsed/Refrac-
tory  CD19+ B-ALL and B-cell lymphomas. Most strik-
ingly, 15 patients could be re-treated after a first failure 
of CAR-T cells and achieved another 60%, with a 1-year 
relapse free survival of 52%. Taken together, these prom-
ising results are in favor of the clinical efficacy of CAR-T 
cells. Given the remarkable activity of CAR T-cells for 
ALL patients, it will be critical to develop clinical trials in 
patients with earlier stages of disease, including very high 
risk ALL in first remission and high risk subsets of ALL at 
first relapse.
Manufacturing of CAR‑T cells
Examples of clinical grade CAR-Ts production include: 
CD19 and CD22 for ALL and lymphomas (and combina-
tions: CD19/22, CD19/20), anti-GD2 for osteosarcoma 
and neuroblastoma, anti-BCMA for multiple myeloma, 
anti-CD30 for Hodgkin and non-Hodgkin lymphoma, 
anti-CCR4 for T cell malignancies and many others [28].
Most CAR-T cells are currently produced using leu-
kocytes collected from the patient who is to receive the 
therapy. The use of autologous cells to manufacture the 
CAR T cells present unique challenges related to cell pro-
duction which include:
• The production of several lots of small quantities of 
cells may cause highly manufacturing costs;
• Differences among subjects’ in terms of biological 
variations, underlying disease and related therapeutic 
treatments lead to product variability;
• Collection and manufacturing failures impede the 
treatment of some of the candidate patients.
In order to optimize the yield of CAR-T cell recovery, 
the enrichment of T cells from starting material (leuka-
pheresis) is desirable. In particular, the use of CD4–CD8 
binding magnetic beads to select T lymphocytes grants a 
better product consistency, even if increasing the manu-
facturing costs and complexity. Following T cell enrich-
ment, the transduction phase is particularly critical. 
Important factors include the choice of vector, quantity 
of vector with respect to cell number, and time and type 
of cells’ exposure to the vector. Finally, appropriate GMP 
compliant quality controls are needed.
Cancer immunotherapy
Increasing interest in the field of immunotherapy has 
been displayed during the last decades thanks to novel 
breakthroughs, leading this strategy to become another 
important pillar of cancer therapy together with sur-
gery, chemotherapy, radiotherapy and targeted therapy. 
Monoclonal antibodies agonistic of immune checkpoints 
revealed to offer durable clinical responses in cancer 
patients with advanced cancers that are usually resistant 
to standard therapy, such as melanoma and non-small-
cell lung cancer.
A brief historical overview
Immunotherapy is based on the idea that a patient’s 
immune system can be stimulated or enhanced to attack 
tumors. One of the first examples of the principles of 
immunotherapy take us back to 1891, when William 
B. Coley, a bone sarcoma surgeon induced an infection 
by injecting streptococcal organisms into a patient with 
inoperable cancer [29]. Despite some degree of toxicity, 
he observed a regression of the tumor. In 1900, Paul Ehr-
lich postulated that if a drug is linked to a toxic chemical, 
it would act like a missile to inactivate unknown invaders, 
including cancer. This scientific theory of “magic bullets” 
has later inspired the scientific community to explore 
numerous molecular cancer therapeutics. In 1975, the 
hybridoma technology enabled the production of mAbs 
specific for a single epitope. mAbs against a specific can-
cer cell protein have been humanized to improve safety 
and efficacy, and in 1997, Rituximab, was the first mAb 
to gain FDA approval for the indication of relapsed or 
refractory, CD20 positive, B-cell, low-grade or follicular 
non-Hodgkin’s lymphoma.
Cancer immunoediting
Changes in the immunogenicity of tumors occur due to 
the anti-tumor response, and the outcome is the gen-
eration of immune-resistant variant; this is one of the 
mechanisms leading to “cancer immunoediting”. Immu-
noediting is a dynamic process, composed of three 
sequential phases: elimination, equilibrium, and escape 
[30]. During the elimination phase, the innate and adap-
tive immunities work together, aiming to destroy the 
developing tumor. At the end of this phase, the host 
remains either free of cancer, or may enter an equilibrium 
phase if a rare cancer cell variant is not destroyed. Dur-
ing this state, adaptive immunity actors (among others: T 
cells, IL-12, and IFN-γ) are required to maintain tumor 
cells in a state of functional dormancy. This phase may 
also represent an end stage of the cancer immunoediting 
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process. But, due to a constant immune selection pres-
sure, tumor cell variants may emerge that are no longer 
recognizable by adaptive immunity (antigen loss vari-
ants or defects in the machinery of antigen processing 
and presentation). They may also become insensitive to 
immune effector mechanisms or induce an immuno-
suppressive state within the tumor microenvironment, 
entering a phase of escape, in which their outgrowth is no 
longer blocked by immunity.
HLA antigens and immunotherapy of malignant diseases
Immune checkpoint inhibitors target co-stimula-
tory (agonistic) or inhibitory (antagonistic) molecules 
expressed on the surface of immune cells rather than on 
the surface of cancer cells, but the malignant transforma-
tion is often associated with defects in surface presenta-
tion of tumor antigen-derived peptides by the HLA class 
I antigen-processing and presenting machinery (APM), 
which is critical for T-cell adaptive immune responses 
against tumors [31, 32]. In a normal state, HLA class I 
antigen processing involves the proteasome complex for 
degradation of the tumor antigen into amino acid pep-
tides fragments. The generated immunogenic tumor 
antigen-derived peptides are translocated across the 
endoplasmic reticulum membrane via the ATP-depend-
ent heterodimeric transporter associated with anti-
gen processing (TAP) complex. The assembly of newly 
synthesized HLA class I heavy chain molecules with 
β2-microglobulin (β2-m) and tumor antigen-derived 
peptides is assisted by transient interactions with cal-
nexin, calreticulin, ERp57 and tapasin [33]. The resulting 
trimers are transported from the ER to the plasma mem-
brane via the trans Golgi and can be presented to cyto-
toxic T lymphocyte (CTL) or NK cells. Abnormalities of 
the APM machinery can take place at the genetic (molec-
ular defects of the heavy chain, immunoproteasome sub-
unit, transporter molecule and β2-m genes) or epigenetic 
level [34]. Epigenetic modulation in gene expression can 
underlie HLA class I APM component defects in malig-
nant cells and includes gene silencing by methylation 
and modification of chromatin structure by histone dea-
cetylation. In some cases, strategies like pharmacologic 
agents inducing DNA hypomethylation or inhibition of 
histone deacetylation can counteract those epigenetic 
mechanisms and restore immunogenic antigen presen-
tation, thus significantly increasing the effectiveness of 
cytotoxic T lymphocyte (CTL) response [34]. HLA class 
I APM component expression and/or function can also 
be affected by the over-activation of multiple oncogenic 
downstream pathways, such as MAPK in several tumor 
systems, including melanoma [35], and epidermal growth 
factor receptor (EGFR) in head and neck cancers. The 
effectiveness of CTL response can be restored via EGFR 
blockade by cetuximab, which triggers the transcription 
factor STAT1 to mediate the synthesis of HLA class I 
molecules and APM components [36, 37].
Immune checkpoint inhibitors
The generation and maintenance of immune responses 
are controlled by a number of coinhibitory as well as 
costimulatory signals that can modulate T-cell receptor-
engagement and its dependent T-cell activation and pro-
liferation (CTLA-4, PD-1, B7-1, LAG-3, CD40L, CD137, 
OX40, and CD28) [38].
Cytotoxic T-lymphocyte antigen 4 (CTLA-4)—a CD28 
homologue—is expressed mainly on the surface of acti-
vated T-cells and T-regulatory cells. CTLA4 plays a cen-
tral role in maintaining immune tolerance by regulating 
T cell co-stimulation at the time of their initial response, 
thus counterbalancing the effect of T-cell receptor/CD3 
activation and CD28 costimulation signals. CTLA-4 
was the first immune-checkpoint molecule to be clini-
cally targeted: ipilimumab became the first successfully 
developed anti-CTLA-4 drug and was approved in 2011 
for the treatment of advanced or unresectable mela-
noma, displaying long-term survival [39]. The clinical 
activity of ipilimumab in combination with fotemustine 
was shown in melanoma patients with brain metastases 
[39]. Similarly, inhibitors of PD-1, another checkpoint 
target expressed on activated T-cells and mediating 
immunosuppression via the binding to its ligands (PD-L1 
and PD-L2), nivolumab and pembrolizumab have been 
approved to treat patients with advanced or metastatic 
melanoma and patients with metastatic, refractory non-
small cell lung cancer.
CheckMate 067 trial results indicate significantly 
longer OS results for nivolumab combined with ipili-
mumab vs nivolumab alone in patients with previously 
untreated advanced melanoma [40]. A phase III study 
(CheckMate 238) is currently ongoing for understanding 
the efficacy of adjuvant immunotherapy with nivolumab 
versus ipilimumab after complete resection of stage IIIb/c 
or stage IV melanoma in patients at high risk recurrence.
Immune checkpoint therapy is also being considered 
for the treatment of mesothelioma, a rare, aggressive 
form of cancer that develops in the lining of the lungs, 
abdomen, or heart [41, 42]. The monotherapy with 
tremelimumab, an anti-CTLA-4 inhibitor, especially in 
an intensified schedule, has shown clinical and immuno-
logical activity in patients with advanced malignant mes-
othelioma (52% of patients achieved disease control, with 
a median duration of 10.9 months) and a good safety pro-
file [42, 43]. However, the same treatment failed to sig-
nificantly prolong OS in patients with relapsed malignant 
mesothelioma, having a safety profile consistent with the 
known CTLA-4 inhibitors [44].
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Other investigations are ongoing to assess whether 
combination regimens provide greater efficacy in meso-
thelioma [i.e. Phase II study of tremelimumab combined 
with the anti-PD-L1 drug durvalumab, having already 
proved the safety and manageability of the drug combina-
tion (NCT02588131)]. Moreover, a Phase III trial is eval-
uating the combination of nivolumab plus ipilimumab vs 
pemetrexed and cisplatin or carboplatin as first-line ther-
apy (CheckMate 743).
Although immune-checkpoint inhibitors showed a 
favorable efficacy/toxicity profile with durable response 
in different cancer types, no predictive biomarkers have 
been yet validated to select patients potentially benefit-
ting from therapy.
Inducible T cell co-stimulator (ICOS) is being evalu-
ated as a pharmacodynamic biomarker associated with 
survival and/or clinical benefit in melanoma treated with 
ipililumab. The use of GSK3359609, an ICOS agonist 
antibody is under evaluation alone and in combination 
with other cancer immunotherapies such as pembroli-
zumab in selected advanced cancers (NCT02723955). 
Among eventual predictive biomarker candidates, the 
mismatch repair status of the tumor has been considered 
and investigated in tumors treated with PD-1 blockade 
[45]. It could predict clinical benefit of immune check-
point blockade with pembrolizumab in progressive meta-
static carcinoma.
Already approved by both the FDA and EMA for mul-
tiple types of tumors, i.e. advanced melanoma, non-small 
cell lung cancer, head and neck cancer, Merkel cell carci-
noma, renal cell carcinoma and hematological malignan-
cies, immune checkpoint inhibitors also appear to have 
significant antitumor activity in multiple other tumor 
types, however not all patients benefit from therapy. 
Efforts should focus on improving the efficacy of immu-
notherapy through the use of combination approaches 
for synergistic effects, and predictive biomarkers of 
response and resistance.
Addressing cancer responsiveness to immunotherapy
Independently of cancer histology, the effectiveness of 
cancer immunotherapy is clearly limited to a subset of 
patients with inflamed tumors [46]. Based on the level 
of T-cell presence and activity, three primary immune 
phenotypes within the tumor microenvironment can be 
identified: immune desert (no cancer immunity), stromal 
excluded (active T-cells unable to reach tumor cells), and 
inflamed (active T-cells in tumor microenvironment not 
functioning properly). However, the number of hypothe-
ses explaining the resistance to immunotherapies exceeds 
the above-recognized tumor immune landscapes. Thus, 
there is a need for a unifying theory to explain the 
response patterns with their resistance mechanisms. Dr. 
Marincola and his collaborators developed the “theory 
of everything”, which assigned resistance mechanisms to 
a specific immune landscape according to its transcrip-
tional expression pattern. Thus, cancers can be defined 
according to their immune contexture with new taxono-
mies derived from global transcriptional patterns [47, 
48]. For example, global transcription analyses of nee-
dle aspiration samples from melanoma metastases from 
patients undergoing immunotherapy showed that half of 
the genes predictive for clinical response were related to 
T-cell regulation, suggesting that immune responsiveness 
might be predetermined by a tumor microenvironment 
conducive to immune recognition [49]. Interestingly, 
the monitoring of the T-cell inflamed gene expres-
sion profiles has shown that responsiveness to check-
point inhibitor therapy is observed almost exclusively in 
immune-active landscape containing IFN-γ—responsive 
genes related to antigen presentation, chemokine expres-
sion, cytotoxic activity, and adaptive immune resistance 
and correlating with clinical benefit [50]. The theory of 
immune contexture is characterized by immune sig-
natures associated with the immunologic constant of 
rejection (ICR), which comprises a set of genes indicat-
ing an active immune engagement and at least a par-
tial rejection of the cancer tissue [51]. However, the 
immune-active landscape is not sufficient alone to pre-
dict immune response. Indeed, other factors are influenc-
ing the immune response: the host’s genetics, the tumor’s 
genetics and the microenvironment [52, 53]. A bioinfor-
matics approach has been used for optimal stratification 
of patients with breast cancers who may benefit from 
immune checkpoint inhibitors. Immune cell-specific 
gene signatures discriminate between immune benefit-
enabled and immune benefit-disabled tumors [54]. Later, 
a clustering based on ICR genes segregates breast cancer 
patients into four different groups: ICR1, 2, 3 and 4. ICR4 
corresponds to patients having the highest expression of 
the ICR gene signature and have a better prognosis com-
pared to other ICR groups [55]. RNA-sequencing data 
from the TCGA consortium were used to define cancer 
immune phenotypes in breast cancer patients. In addi-
tion, somatic mutations and copy number alterations 
were mined to capture genetic features associated with 
such immune phenotypes. With this approach, it has 
been showed that MAPK modulation might enhance the 
therapeutic efficacy of immunomodulatory approaches 
in breast cancer. Interestingly, these main findings were 
validated in an independent meta-cohort of breast can-
cer samples [55]. Subsequently, by mapping gene signa-
tures according to their expression in different immune 
landscapes of breast, lung, colon cancers, and melanoma, 
the theory of the “two option choice” was stipulated. 
This theory proposes that tumors evade recognition 
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by the immune competent host by either adopting a 
“clean” oncogenic process, free of immunogenic stimuli 
(immune silent tumors) or, display a profile that tends 
towards immune recognition (immune active tumors) 
but resists rejection by recruiting compensatory immune 
suppressive processes. Thus, immunotherapy is likely to 
be most successful in targeting immune active tumors, 
while silent tumors should be approached with only ther-
apeutic manipulations that affect the intrinsic cancer cell 
biology in order to be clinically successful.
Molecular targeted therapies: JAK inhibitors 
in autoimmune and inflammatory diseases
Cytokines are pivotal in the maintenance of an appro-
priate immune response. Dysregulation of cytokine 
activity results in the loss of the immune system homeo-
stasis, and the targeting of cytokine receptors has been 
an effective means of treating immune-related disorders. 
In the last few years, research efforts have been directed 
towards cytokines’ intracellular signaling pathways. Upon 
binding to their specific receptor, cytokines trigger a cas-
cade of events involving activation of the tyrosine kinase 
of the Janus family, also known as JAKs, as the first and 
critical step.
Inhibition of JAK enzymatic activity has proved suc-
cessful for some immune-mediated pathologies. So far, 
four JAKs inhibitors have been approved for clinical use. 
Ruxolitinib is a JAK2/JAK1 inhibitor currently utilized 
for the treatment of myeloproliferative disorders.
Tofactinib, a JAK3/JAK1 inhibitor, is approved for the 
treatment of rheumatoid arthritis, psoriatic arthritis and 
ulcerative colitis. It was recently shown that one of JAK3/
JAK1 inhibitors, tofacitinib, is efficacious in ameliorating 
several aspects of the pathology associated with a murine 
model of Systemic Lupus Erythematosus and a Phase Ib 
trial in Lupus patients was recently concluded at National 
Institutes of Arthritis Musculoskeletal and Skin Diseases 
(NCT02535689).
Moreover, JAK inhibitors are being investigated for sev-
eral other pathologies including alopecia, vitiligo, psoria-
sis, inflammatory bowel disease (IBD), atopic dermatitis 
as well as for genetically-inherited diseases characterized 
by overproduction of Interferons.
Interestingly, only mild toxicity was observed in 
patients treated with these drugs even if these drugs tar-
get several cytokines, including interferons, hormones 
and growth factors. Side effects included increased rates 
of infections, low hemoglobin levels, and augmented cir-
culating lipoproteins, creatinine and transaminases. The 
blockade of a single JAK could potentially reduce toxic-
ity for these drugs, especially in the setting of long-term 
administration. Therefore, more selective JAK inhibitors 
are currently being developed and are currently being 
tested. If the increased selectivity will affect their efficacy 
remains to be seen.
Cell therapy and adoptive cell therapy
Mesenchymal stromal cells (MSCs)
Mesenchymal stromal cells display immunoregulatory 
and regenerative properties [56]. The relative ease of har-
vesting MSCs, and their stable phenotype upon in vitro 
culture, render MSCs an attractive tool for cell-based 
therapy in alloimmunity, autoimmunity and inflamma-
tion. This is reflected by the increased numbers of pub-
lished clinical trials—for example, in GvHD [57], Crohn’s 
disease (CD) [58] and multiple sclerosis [59]—and of 
ongoing clinical trials.
MSCs are non-hematopoietic cells expressing differ-
ent surface molecules (including CD90, CD73, CD105, 
CD29, CD44, and CD166), but lacking the expression 
of endothelial or hematopoietic markers (CD31, CD45, 
CD43, CD14, CD11b), major histocompatibility com-
plex (MHC) class II molecule, and costimulatory proteins 
(CD80, CD86, CD40) [60, 61].
MSCs display low engraftment rates after therapeutic 
infusion, and the engraftment is not directly proportional 
to response to treatment. These cells might carry out 
their functions through a “hit and run” mechanism, while 
limiting eventual therapy related long-term risks with 
their short persistence [62].
Upon in vitro culture, and -although to a lesser extent- 
in in vivo models, MSCs trigger the instant blood medi-
ated inflammatory reaction (IBMIR). The activation 
of coagulation and complement cascades may activate 
immune responses. Induction of IBMIR is dose-depend-
ent and increases after prolonged ex  vivo expansion: 
cell doses of low-passage clinical-grade MSCs currently 
administered in clinical trials elicit only minor systemic 
effects [63].
The immunomodulatory properties of MSCs, through 
the down-modulation of inflammatory responses, the 
increase of T-reg cell frequencies and the enhancement 
of tissue repair and homeostasis, represent the ration-
ale for their application in several clinical settings [57, 
64, 65], including intestinal inflammation in both acute 
GvHD and IBD.
Despite the availability of a wide range of therapeutic 
strategies, the management of severe and refractory cases 
of IBD represents a big clinical challenge. In this arena, 
MSCs stand out as a new therapeutic option. The dem-
onstration that biological characteristics of the MSCs 
derived from CD patients are similar to those derived 
from healthy donors [66] has represented the basis for an 
autologous approach of anti-inflammatory/reparative cell 
therapy in patients with refractory CD.
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In a Phase I/II study, the intrafistular injection of 
autologous bone marrow-derived MSCs (BM-MSCs) 
from patients with refractory fistulizing CD revealed to 
be safe and effective, obtaining a significant reduction of 
both Crohn’s Disease Activity Index (CDAI) and Perianal 
Disease Activity Index (PDAI). Seventy percent of the 
patients experienced complete and sustained healing of 
fistula tracks, and 30% a partial response [67].
In a Phase I study it has been observed that the intrave-
nous injection of autologous MSCs for refractory lumi-
nal CD has an optimal safety profile and efficacy in 4 out 
of 10 treated patients [58]. Recently, a multicenter Phase 
III randomized study compared the efficacy of third-
party adipose tissue-derived MSCs (AT-MSCs) (indus-
trial preparation) with a placebo. MSCs were injected 
intra-lesion in refractory fistulizing CD patients. The 
primary endpoint combining both clinical assessment of 
fistula closure and MRI found 50% combined remissions 
24 weeks after treatment in the MSC group vs 34% in the 
placebo group [68]. Autologous/3rd party BM-/AT-MSCs 
therefore provide an effective therapy for patients with 
refractory fistulizing CD who do not respond to conven-
tional and/or biological treatments.
Adoptive cell therapy
Antigen specific T-cell therapies contributed to ame-
liorate the haplo-transplant outcome in the last decade, 
which saw a drastic reduction in transplant-related mor-
tality: 6% after 2005 vs 33% before 2005 (Pavia cohort, 
unpublished data). Adoptive T-cell therapy is useful in 
reconstituting specific immunity and in the treatment of 
Epstein–Barr virus (EBV)-related post-transplant lym-
phoproliferative disorder (PTLD) [69, 70], HHV6-related 
transplant-rejection, severe human Cytomegalovirus-
related colitis in patients with primary immunodeficiency 
[71], polyomavirus BK infections [72], and progressive 
multifocal leukoencephalopathy associated with poly-
omavirus JC [73]. Remaining problems related to the 
implementation of this approach are: (i) producing viral-
specific T-cells targeting simultaneously multiple viruses, 
(ii) reducing production time, and (iii) producing bio-
logical agent with efficacy in recipients of seronegative 
donors [74].
Several attempts have already been done in those 
directions, such as monoculture-derived multi-specific 
cytotoxic T-lymphocytes (CTL) against CMV and EBV, 
several serotypes of adenovirus that were proven to be 
safe and efficient means to restore virus-specific immu-
nity in the immunocompromised host [75, 76], and third-
party EBV-specific CTLs for PTLD, which showed 42% 
complete remission (CR) at 6  months and 70% overall 
survival at 2 years, although long-term results were less 
satisfactory [77–79].
Moreover, adoptive cell therapy has also been imple-
mented for cancer treatment. Cell therapy with EBV-tar-
geted autologous CTLs was shown to be safe, capable of 
inducing specific immunologic responses, and associated 
with objective responses and control of disease progres-
sion in patients with stage IV nasopharyngeal carcinoma 
resistant to conventional treatments [80]. The results are 
encouraging, although further improvements to the clini-
cal protocols are clearly necessary to increase anti-tumor 
activity, and promising implementations are underway, 
including harnessing the therapeutic potential of CTLs 
specific for subdominant EBV latent cycle epitopes, and 
delineating strategies aimed at targeting immune eva-
sion mechanisms exerted by tumor cells [81]. Another 
recently developed application is in the context of Phila-
delphia chromosome-positive acute lymphoblastic leu-
kemia  (Ph+ ALL): 3 treatment-refractory patients were 
treated with autologous or allogeneic p190BCR-ABL-
specific CTLs, achieving molecular or hematologic CR 
upon the emergence of p190BCR-ABL-specific T-cells in 
the bone marrow [82].
Diabetes
Diabetes is a metabolic disorder that is characterized by 
chronic hyperglycemia due to progressive loss of pan-
creatic β-cells, which, over time, can lead to several well-
recognized and debilitating complications. The Qatar 
National Diabetes strategy 2016–2022 stated that diabe-
tes is a major health challenge with a prevalence that is 
over double that of the world population, at 17%. To date, 
there is no permanent treatment available for diabetes. 
Cell therapy might prove to be the best approach to treat 
type 1 diabetes (T1D), monogenic diabetes, and severe 
cases of type 2 diabetes (T2D).
Cell‑based immunomodulation: MSCs
Mesenchymal stromal cells are considered one of the 
most interesting candidates for the treatment of T1D 
based on their anti-inflammatory and immunomodula-
tory capacities, associated with poor immunogenicity 
that enables them to escape the host immunesurveillance. 
Several pre-clinical studies, in streptozocin-induced dia-
betic mouse models, showed that MSCs protect from 
diabetes or revert the diabetic phenotype [83–86]. A 
Phase I clinical trial was conducted in Sweden, where 
adult patients recently diagnosed with T1D received 
autologous BM-MSCs. During the first year after diag-
nosis, a preserved or even increased C-peptide response 
to a mixed-meal tolerance test in treated patients was 
observed, while no adverse events were registered [87]. 
Apparently, MSCs derived from T1D patients, despite 
some clear transcriptional differences, do not dem-
onstrate a significant difference from healthy controls 
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in immunosuppressive activity, migratory capacity, or 
hemocompatibility [88].
Beta‑cell replacement
Insulin replacement for T1D is burdened by relatively 
low clinical efficacy, low compliance to glycemic control 
(roughly about 1/4 of patient with type 1 reaches thera-
peutic targets) [89], high and increasing cost (about 3% 
increase/year), and high impact on quality of life [90–92] 
thus requiring alternative approaches. Beta-cell replace-
ment can be obtained from different sources, such as 
transplantation of whole pancreas or pancreatic islets, 
pancreatic duct stem cells, α-cells, human embryonic 
stem cells (hESCs) and induced pluripotent stem cells 
(hiPSCs), and β-cell expansion both in  vivo and ex  vivo 
[93].
Islet transplantation
Transplantation of islets of Langerhans consists of 
implantation of different degrees of purified endocrine 
pancreatic tissue in the recipient’s hepatic portal sys-
tem. The transplantation allows the restoration of the 
functional β-cells in diabetic patients [94], halting the 
late complications of diabetes, namely vasculopathy, 
retinopathy, nephropathy and neuropathy, in the face of 
a prolonged immunosuppressant therapy. From 1989 to 
2017, 211 patients were transplanted at San Raffaele Sci-
entific Institute, Italy (which ranks 2nd in the world for 
this procedure), granting patients long term insulin inde-
pendence [94]. However, organ shortage, uncertain risk/
benefit balance (i.e. absence of clear indications, absence 
of functional outcome definition, anti-rejection drugs, 
surgical risk, and long-term success rates) and financial 
barriers represent the major limitation for the extensive 
application of the procedure.
Pluripotent stem cells
Stem cell therapy is becoming a concrete opportunity 
to treat various diseases. In particular, for a disease like 
T1D, caused by the loss of a single specific cell type that 
does not need to be transplanted back in its originat-
ing site to perform its function, a stem cell-based cell 
replacement therapy seems to be the ideal cure. ViaCyte 
(formerly Novocell) has optimized the protocol for mak-
ing pancreatic progenitors from human pluripotent stem 
cells (hPSCs) [95, 96]. A clinical trial for diabetic patients 
treated with human embryonic cells (hESC)-derived pan-
creatic progenitors macroencapsulated in ENCAPTRA is 
currently ongoing at San Raffaele Scientific Institute, Italy, 
in collaboration with Viacyte (US), Brussels University 
(Belgium), Leiden University (Netherlands) and  Nestlè 
Institute of Health Sciences (Switzerland) (http://viacy 
te.com/clini cal/clini cal-trial s/). Before transplanting 
those progenitors, the co-expression of two transcription 
factors PDX1 and NKX6.1 must be confirmed to assure 
their differentiation inside the body within few weeks 
into islet cells [97]. Recently, Abdelalim’s group was able 
to establish a highly efficient protocol to generate around 
90% of hPSC-derived pancreatic progenitors expressing 
the key transcription factors  (PDX1+/NKX6.1+) required 
for β-cell maturation [98, 99], indicating a dramatic 
improvement in the differentiation process. Interest-
ingly, a novel pancreatic progenitor population has been 
recently generated from hPSCs, expressing NKX6.1 but 
not PDX1  (PDX1−/NKX6.1+). The characterization of 
this novel population showed pancreatic endocrine pre-
cursor features, defining it as a potential new source for 
pancreatic β-cells [98, 99]. Furthermore, hPSCs, includ-
ing hESCs and human induced PSC (hiPSCs) can pro-
vide a renewable source of functional pancreatic β-cells 
to study and treat diabetes, because hPSC-derived β-cells 
can be closer in nature to the in vivo β-cells than those 
differentiated from other types of stem cells. hiPSC tech-
nology allows to directly generate hPSCs from diabetic 
patients, providing cells genetically identical to patients 
to be used for in  vitro disease modeling and eventually 
cell-based therapies [97]. In Qatar, Abdelalim’s team has 
generated several hiPSC lines from insulin resistant and 
diabetic patients, with in  vitro differentiation capacity 
into different cell types including β-cells and insulin-tar-
get cells that can be used to understand the pathophysiol-
ogy of the diabetes.
Continuous subcutaneous insulin infusion using 
computerized program
A pilot study is ongoing in Sidra Medicine, Qatar, aiming 
to evaluate the effectiveness of a unified computerized 
program for the initiation of continuous subcutaneous 
insulin infusion (CSII) in T1D patients in Qatar. CSII 
settings were performed using a specific computer-
ized program (built in-house), calculating basal rates, 
bolus wizard and sensor settings, once entered with age, 
HbA1c, basal/bolus insulin dose, wake-up and school 
time for each patient.
A significant increase of total insulin dose by 27% and 
significant decrease of HbA1c by 1.5% was detected at 
the end of the study.
Although conducted on a small cohort (34 patients) 
and a short follow-up period (6  months), the study 
showed that unified computerized program for CSII ini-
tiation may improve glucose control in T1D patients.
Advanced therapeutic techniques
Thymus transplantation
Thymus transplantation is a promising strategy for the 
treatment of athymic complete DiGeorge syndrome 
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(cDGS), characterized by profound T-cell deficiency and 
associated with a hemizygous microdeletion at chromo-
some 22q.11, CHARGE (Coloboma, heart defects, atresia 
choanae, retardation of growth and development, genital 
abnormalities, ear abnormalities/deafness) syndrome, 
mutations in TBX1, deletions at chromosome 10p13-14, 
or fetal toxin exposure from glucose, ethanol, or retinoic 
acid.
The survival of patients with this anomaly is usually 
low, with most patients dying before the age of 2 years. 
Bone marrow or peripheral T-cell transplant in Di 
George patients seems to slightly improve the survival 
rate [100], whilst thymus transplantation significantly 
increases the survival rate, with one study reporting the 
survival of over 60% (n = 60) of patients surviving over 
15  years post-transplant [101]. Eighteen patients with 
cDGS underwent transplantation with allogeneic cul-
tured thymus: 2  patients died early  of pre-existing viral 
infections, and 1 late death occurred from autoimmune 
thrombocytopenia. Evidence of thymopoiesis devel-
oped at 5–6 months after transplantation in 14 patients, 
who were able to clear pre-existing infections and those 
acquired later. Autoimmune complications were seen in 8 
of 18 patients, including thyroiditis, hemolysis, thrombo-
cytopenia, and neutropenia.
In the future, a combined approach of newborn screen-
ing, allowing earlier recognition of the disease and less 
infections, and thymus cryopreservation for a timely 
readiness and better HLA matches, could eventually 
improve the survival rate.
Intrauterine surgery
Intrauterine surgery is an intervention performed on a 
fetus while still in utero, with the goal to correct an alter-
ation in the normal fetal development. This cutting-edge 
procedure considers the fetus not merely a tissue, but a 
patient, inside of another patient: the mother.
More than a simple surgery, it is rather considered “an 
enterprise”, including a multidisciplinary involvement of 
teams collaborating in the same operating theater: sur-
gery, perinatology, neonatology, anesthesiology, cardiol-
ogy, and interventional radiology. Both life-threatening 
fetal diseases (such as cystic adenomatoid malformation, 
sacrococcygeal teratoma, twin-twin transfusion syn-
drome, valvular obstruction, urinary obstruction) and 
non-life-threatening complications, (e.g. Fetal Mye-
lomeningocele or Open Spina Bifida) can be addressed 
with this technique.
Myelomeningocele is a degeneration of the neural 
tube. In early gestation, the neural tube is open but has 
a normal cytoarchitecture, while neuronal deteriora-
tion occurs later in utero, coming from the intrauterine 
environment. Ultrasound reports show good leg move-
ments of the fetus at 16  weeks, but deterioration by 
birth. Strikingly, a randomized trial comparing prenatal 
vs postnatal Myelomeningocele surgery was stopped for 
efficacy in the prenatal arm [102]. Another randomized 
trial showed how intrauterine treatment of patients 
with high risk severe isolated congenital diaphragmatic 
hernia grants a significant survival benefit for the new-
borns with good maternal outcomes [103].
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